This study will enroll a total of 16 patients with advanced pancreatic cancer at Cedars-Sinai Medical Center. All subjects will receive combination therapy of gemcitabine, nab-paclitaxel, and L-glutamine. The study investigates what the appropriate dosage of L-glutamine is so that there is the lowest risk of side effects, and whether the supplement will make standard chemotherapy of gemcitabine and nab-paclitaxel more effective in treating advanced pancreatic cancer.

开始日期2021-05-13

申办/合作机构

Cedars-Sinai Medical Center

[+1]

NCT04684381 / Completed临床4期

A Phase 4, Open-Label, Single-Center Study to Assess Pharmacokinetic Characteristics and Safety of Endari in Patients With Sickle Cell Disease

L-glutamine has been approved in the US to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. The purpose of this single-center, open-label, phase 4 study is to evaluate the pharmacokinetic characteristics and safety of L-glutamine in patients with SCD.

开始日期2021-01-04

申办/合作机构

Emmaus Medical, Inc.

NCT05106101 / Completed临床1期

A Pilot/Phase 1, Interventional, Open-label, Multi-center Study to Assess the Safety and Efficacy of L-glutamine Treatment in Patients With Diverticulosis

The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.

开始日期2019-07-19

申办/合作机构

Emmaus Medical, Inc.

100 项与 Emmaus Medical, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Emmaus Medical, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Emmaus Medical, Inc. 相关的文献（医药）

2023-09-06·Cells

Human Oral Mucosa as a Potentially Effective Source of Neural Crest Stem Cells for Clinical Practice.

Article

作者: Narwani, Kavita ; Calhoun, Colonya C ; Uyanne, Jettie ; Terrazas, Jesus ; Royce-Flores, Jun ; Al Dahan, Mais ; Crum, Eric ; Niihara, Yutaka ; Bardag Gorce, Fawzia ; Ferrini, Monica

We report in this study on the isolation and expansion of neural crest stem cells (NCSCs) from the epithelium of oral mucosa (OM) using reagents that are GMP-certified and FDA-approved for clinical use. Characterization analysis showed that the levels of keratins K2, K6C, K4, K13, K31, and K15-specific to OM epithelial cells-were significantly lower in the experimental NCSCs. While SOX10 was decreased with no statistically significant difference, the earliest neural crest specifier genes SNAI1/2, Ap2a, Ap2c, SOX9, SOX30, Pax3, and Twist1 showed a trend in increased expression in NCSCs. In addition, proteins of Oct4, Nestin and Noth1 were found to be greatly expressed, confirming NCSC multipotency. In conclusion, our study showed that the epithelium of OM contains NCSCs that can be isolated and expanded with clinical-grade reagents to supply the demand for multipotent cells required for clinical applications in regenerative medicine. Supported by Emmaus Medical Inc.

2022-06-15·Cancer Research

Abstract 1752: Switchable binding of TecApta to Atezolizumab provides the possibility of enhancing the therapeutic effects of this immune checkpoint inhibitor

作者: Oliva, Joan ; Pereira, Carlos ; Grondin, Jessica ; Takahashi, Sola ; Elshimali, John ; Atefi, Mohammad Sadegh ; Olsem, Gary ; Yang, Julie ; Futamura, Akiko ; Doueiri, Rami ; Bourgeois, Lindsay ; Sich, David

AbstractOne of the main goals of cancer therapeutics is to develop smart molecules that can deliver drugs or immunogens to cancer cells within the tumor, while avoiding the toxicity to normal cells. Lately, immune checkpoint inhibitors have shown significant effects in the field of cancer treatment. Atezolizumab is an immune check point inhibitor specific to PD-L1. In order to potentiate anti-tumor aspects of Atezolizumab, we have developed TecApta, a switchable single strand DNA oligonucleotide aptamer that specifically binds to this antibody with a high affinity and specificity. However, TecApta is detached from Atezolizumab upon binding of this antibody to its target PD-L1. This switchable aspect of TecApta makes it a suitable drug carrier for targeting cancer cells within the tumor microenvironment. We have developed modified versions of TecApta which include either the chemotherapy drug, gemcitabine, or the immune activator, TLR9A. Based on our in vitro data, both versions are biologically active. The gemcitabine sensitive cell line MDA-MB-231/Luc exhibits similar IC50s (20nM) for both gemcitabine-linked-TecApta (GMZ-TecApta) and the free unbound gemcitabine. Moreover, the same concentrations of TLR9A-linked-TecApta (TLR9A-TecApta) and the free TLR9A show similar effects in inducing TLR9 receptors in a cell-based assay. These results suggest that possibly GMZ-TecApta and TLR9A-TecApta can be carried by Atezolizumab and released within the tumor microenvironment, where they may induce apoptosis or aggravate an immune reaction, respectively. Animal studies will be conducted in the future to investigate the possibility of such favorable outcomes.Citation Format: Mohammad Sadegh Atefi, Sola Takahashi, David Sich, Jessica Grondin, Rami Doueiri, Lindsay Bourgeois, Gary Olsem, Akiko Futamura, Julie Yang, Joan Oliva, John Elshimali, Carlos Pereira. Switchable binding of TecApta to Atezolizumab provides the possibility of enhancing the therapeutic effects of this immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1752.

2021-11-05·Blood

New Anti-Cancer Drug Compounds to Treat Mutated Waldenstrom Myd88 L265P

作者: Niihara, Yutaka ; Ochiai, Jun ; Oliva, Joan ; Villanueva, Larakaye

AbstractWaldenstrom Macroglobulinemia (WM) is a non-Hodgkin lymphoma, often associated with production of monoclonal IgM in a large amount. The increased level of IgM leads to the increased level of blood viscosity, potentially causing spontaneous bleeding, headaches, vertigo and could lead to stroke and coma. WM is a rare disease, affecting around 3 cases per million per year in the USA. Different chromosomal abnormalities can be cause of WM, but the most common mutation detected in WM is the mutation L265P on the Myd88 protein, a downstream regulator of TLR4 pathway. While today there are many treatment options to manage WM, including plasmapheresis, monoclonal (rituximab) and immunomodulating drugs (halidomide), cytokines, mTOR inhibitors (everolimus), Burton tyrosine kinase (Ibrutinib), there isn't a single effective enough treatment for WM that are widely used.In this study, MWCL-1 cells (adult WM), expressing the Myd88 L265P mutation, were used to test different drugs to monitor their effect in cell proliferation and apoptosis activities, in comparison to midostaurin (an inhibitor of FLT3), for 24 hours treatment. MWCL-1 cells were cultured in RPMI1640, in presence of 2, 10 and 25 % of fetal bovine serum (FBS). 25 % FBS was tested to be as close as possible with the level of serum present in human blood. Adipose stromal cells (ASC) were used as a reference control, in absence of serum. Compounds A (targeting TLR pathway, through IRAK-4) was used at various concentrations (0.05 to 100 µM), over 24h of treatment, in combination or not with compound B (targeting the DNA). Compound A has a high affinity for IRAK4, downstream kinase of TLR pathway. TLR pathway activation in leukemia, through Myd88 and IRAK4, is involved in the pro-inflammation response but it is also inducing proliferation and cell survival. Compound B is an inhibitor of the poly (ADP-ribose) polymerase (PARP), which are enzymes that are involved in DNA transcription, cell cycle regulation and DNA repair.In the ASC, the caspase activity of compound A was not different from the control, but the number of cells was lower at 50 and 100 µM, indicating that the compound A was delaying the cell growth. The number of MWCL-1 cells decreased only at higher compound A concentration (50 and 100 µM), during a 24h treatment, at 2, 10 and 25 % FBS. When the cells were treated with the compound A, the level of caspase 3/7 activity was elevated only at the highest concentration (50 and 100 µM), which is consistent with the decreased number of cells, at 2, 10 and 25 % FBS. MWCL-1 were more resistant to the anti-cancer effect of the compound A at 25 % FBS, indicating that it could work on patients because 25 % FBS is close to the patient's serum level. Midostaurin, from 0.05 to 100 µM, was reducing the number of cells and increasing the caspase 3/7 activity in the cells, in a dose response manner, at 2, 10 and 25 % FBS. However, data suggest that at the highest midostaurin dose (100 µM), compound A was more efficient than midostaurin (100 µM). Compound B alone, at 10 µM, had no effect on the MWCL-1 cell number and on the caspase 3/7 activity, for the 2, 10 and 25 % FBS. However, a synergistic effect was demonstrated when compound B (10 µM) was combined with compound A at 50 and 100 µM. The combination decreased the number of MWCL-1 cells and increased the caspase activity 3/7, more so than it was compared to the single compound studies. Our data suggest that it would be possible to lower the posology of the compound A when it will be given to the patients, in combination with the compound B.In conclusion, the data showed compound A alone or combined with the compound B decreased the level of proliferation and increased the level of apoptosis of MWCL-1 cells, cultured with 2 to 25 % of FBS. The use of compound A at high concentration to reduce the number of MWCL-1 reflect the difficulties to treat WM patient with the existing approved drugs. Further studies will be necessary to understand more the molecular mechanism affected by the compound A and/or B in the TLR-IRAK4 pathway, and to study their effect in vivo.DisclosuresOliva: Emmaus Lifesciences, Inc.: Current Employment. Villanueva: Emmaus Lifesciences, Inc.: Current Employment. Ochiai: Emmaus Lifesciences, Inc.: Ended employment in the past 24 months. Niihara: Emmaus Lifesciences, Inc.: Current Employment.

项与 Emmaus Medical, Inc. 相关的新闻（医药）

2024-09-28

·佰傲谷BioValley

因安全问题，辉瑞撤回一款镰状细胞病药物

2024年9月25日，辉瑞宣布自愿从目前所有获批的市场中撤回所有批次的镰状细胞病（SCD）治疗药物Oxbryta（voxelotor）。同时，辉瑞还将停止所有正在进行的voxelotor的临床试验和全球扩展访问计划。存在安全问题 Oxbryta是一种每日1次口服的SCD药物，于2019年11月获得美国首次批准，目前已经在全球超过35个国家/地区获批上市。Oxbryta由辉瑞于2022年以54亿美元收购Global Blood Therapeutics获得。根据报道，辉瑞对于Oxbryta的决定是基于现有的全部临床数据，数据表明Oxbryta在SCD患者中的总体益处不再高于风险，患者的血管闭塞危象和致命事件已失衡，需要进一步评估。辉瑞已将这些发现告知监管机构，并决定自愿将Oxbryta从市场上撤出并停止分销和临床研究，同时进一步审查现有数据并分析结果。目前，辉瑞正在和临床医生讨论替代疗法。辉瑞表示，将继续分析和审该药物的安全性结果。值得注意的是，该决定是在欧洲监管机构开会审查Oxbryta安全性的前一天做出的。EMA于周四建议暂停对Oxbryta的许可，EMA审查Oxbryta的原因是在两项研究中，一项试验死亡人数高于预期，另一项研究服用Oxbryta的患者比服用安慰剂的患者死亡人数更多。辉瑞的SCD布局辉瑞在镰状细胞病上曾寄予厚望，在2022年收购Global Blood Therapeutics时，预测Oxbryta和另外两款在研镰状细胞病药物未来的销售额可能超过30亿美元。据辉瑞财报，2023年Oxbryta的全球销售额为3.28亿美元。Oxbryta在2024年第二季度的销售额为9200万美元。 Oxbryta的失败，将会导致辉瑞失去一大部分收入，也使得辉瑞在镰状细胞病上暂时失利。但是辉瑞子公司Global Blood的两款SCD在研药物inclacumab和osivelotor已经推进到3期临床，尤其是osivelotor（GBT-601）被认为是Oxbryta的接任者，去年年底发布的数据显示出积极的前景。来自osivelotor的2/3期研究A队列中35例SCD患者，其中17人接受了100mg剂量的osivelotor，18人接受150mg剂量。经过12周的治疗后，两个剂量组的患者的血红蛋白水平平均提高了3g/dL。 SCD药物市场 SCD是一种遗传性血液病，其中血红蛋白S（HbS）聚合导致红细胞镰状化，从而导致血管炎症和溶血性贫血。血管炎症与红细胞镰状化的出现可导致急性疼痛危象或血管闭塞危象，以及进行性终末器官损伤，包括中风。根据报道，SCD是全球重大公共卫生难题，每年有大约500万人死于SCD。相较于SCD的患病人群，SCD治疗药物选择不多： Hydroxyurea是最早获得批准的SCD药物，但是其具有严重的毒副作用，因此使用受到限制； Emmaus Medical的Endari，于2017年获得FDA批准，是20年来首个获得批准的SCD新药；诺华的Adakveo，于2019年获得FDA批准，是首个SCD治疗的靶向药物； Global Blood的Oxbryta，于2019年获得FDA批准，后来Global Blood被辉瑞收购； bluebird bio（蓝鸟生物）的Lyfgenia，于2023年12月获得FDA批准，是一款细胞基因治疗产品，旨在通过一次性给药实现长期乃至终身有效，售价高达310万美元； Vertex和CRISPR Therapeutics的Casgevy，于2023年12月获得FDA批准，是一款CRISPR基因编辑疗法，售价为220万美元。 Oxbryta的失败，使得SCD患者的可选择药物少了一个。同时，两款基因治疗的获批虽然给患者提供了更好的治疗前景，但是治疗费用的门槛使得真正使用这两款药物的患者不多。参考资料： 1.https://www.biopharmadive.com/news/pfizer-oxbryta-withdraw-pull-market-sickle-cell/728155/ 2.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

并购财报临床3期临床2期

2024-09-26

·Outsourcing Pharma

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

The withdrawal decision was prompted by clinical data indicating that the overall benefit of Oxbryta “no longer outweighs the risk” in its target patient population, the company said in a public release . Specifically, the trials outline an “imbalance” in vaso-occlusive crises and fatal events that the company will assess further. The move to stop clinical trials of the drug will last while Pfizer further reviews the available data and investigates the findings. Sickle cell disease is a genetic blood disorder where patients have a mutation in hemoglobin, a protein found in red blood cells. This leads the protein to clump together, causing cells to have a sickle shape that can block blood vessels and carry less oxygen, leading to acute pain and anemia. Oxbryta, whose generic name is voxelotor, is an oral small molecule drug that was first approved by the US Food and Drug Administration (FDA) for the treatment of sickle cell disease in 2019, with an EU approval granted in 2022. The drug is designed to make hemoglobin better at carrying oxygen and less prone to clumping together, making red blood cells more functional. The treatment was previously developed by the U.S. firm Global Blood Therapeutics before the company was snapped up by Pfizer for $5.4 billion in 2022 , and bagged Pfizer $328 million in revenues in 2023 . The big pharma company has notified regulators about the data and doesn’t expect the event to impact its full-year 2024 financial guidance. Nevertheless, the company’s stock price on the New York Stock Exchange slumped by more than 1% at the news yesterday (Wednesday 25th September). googletag.cmd.push(function () { googletag.display('text-ad1'); }); Emphasizing Pfizer’s focus on patient safety, chief medical officer and head of worldwide medical and safety, Aida Habtezion, said in the company release that the Pfizer’s “primary concern is for patients who suffer from SCD, which remains a very serious and difficult-to-treat disease with limited treatment options. We advise patients to contact their physicians to discuss alternative treatment while we continue to investigate the findings from our review of the data.” The global market for sickle cell disease was worth $2.25 billion in 2022 and is expected to grow by 20.1% per year to $9.84 billion by 2030. The main players in the market have included Pfizer with Oxbryta, Novartis with the antibody Adakveo (crizanlizumab) and Generex Biotechnology’s Emmaus Medical with Endari (L-glutamine). In 2017, Endari became the first branded drug for sickle cell disease in decades when it was greenlit by the U.S. FDA. Another driver for the sickle cell disease market is gene therapy, with the first cell-based gene therapies – Casgevy by Vertex Pharmaceuticals and Lyfgenia by Bluebird Bio – approved by the U.S. FDA in late 2023 .

上市批准基因疗法

2024-02-04

·赛柏蓝

34个重磅专利到期药物（附名单）

作者 | 骎丹翼来源 | 药智网2024年，美国将有34款药物的关键专利到期，其中强生的重磅炸弹药物Xarelto(rivaroxaban)最值得关注。以下为笔者盘点的关键专利到期的药物信息，包含销售商、获批时间、适应症、销售额等数据。1.Auryxia(ferric citrate)销售商：Keryx Biopharmaceuticals,Inc.获批时间：2014年9月5日适应症和用途：控制透析患者的血清磷水平、未接受透析的成年慢性肾病患者的缺铁性贫血。关键专利到期时间：2024年2月18日药物专利数量：14销售额：预计2023年净产品收入1.75-1.8亿美元2.Spravato(esketamine hydrochloride)销售商：Janssen获批时间：2019年3月5日适应症和用途：患有难治性抑郁症(TRD)的成人、具有自杀想法或行为的重度抑郁症(MDD)成人的抑郁症状。关键专利到期时间：2024年3月5日药物专利数量：6销售额：2023年前三季度4.83亿美元3.Phexxi(citric acid;lactic acid;potassium bitartrate)销售商：Evofem获批时间：2020年5月22日适应症和用途：女性避孕。关键专利到期时间：2024年3月6日药物专利数量：4销售额：2022年1.68亿美元4.Exparel(bupivacaine)销售商：Pacira Pharms获批时间：2011年10月28日适应症和用途：长效酰胺类局麻药，用于术后镇痛。关键专利到期时间：2024年3月22日药物专利数量：9销售额：2023年净产品收入5.38亿美元5.Ionsys(fentanyl hydrochloride)销售商：The Medicines Co获批时间：2015年5月22日适应症和用途：芬太尼离子电渗透皮系统，用于对需要阿片类镇痛的住院成人进行急性术后疼痛的短期管理。关键专利到期时间：2024年4月1日药物专利数量：86.Contrave(bupropion hydrochloride;naltrexone hydrochloride)销售商：Nalpropion获批时间：2014年9月10日适应症和用途：一种氨基酮类抗抑郁药和阿片类拮抗剂的组合，可作为低热量饮食和增加体力活动的辅助手段，以实现长期体重管理。关键专利到期时间：2024年4月21日药物专利数量：207.Natroba(spinosad)销售商：Parapro获批时间：2011年1月18日适应症和用途：多种体外寄生虫适应症。关键专利到期时间：2024年4月28日药物专利数量：28.Rydapt(midostaurin)销售商：诺华获批时间：2017年4月28日适应症和用途：FLT3突变的急性髓系白血病和系统性肥大细胞增多症。关键专利到期时间：2024年4月28日药物专利数量：2销售额：2022年4.2亿美元9.Tralement(cupric sulfate;manganese sulfate;selenious acid;zinc sulfate)销售商：Am Regent获批时间：2020年7月2日适应症和用途：口服或肠内营养不可能、不足或禁忌时，作为肠外营养的锌、铜、锰和硒的来源。关键专利到期时间：2024年4月30日药物专利数量：110.Radicava(edaravone)销售商：Mitsubishi Tanabe获批时间：2017年5月5日适应症和用途：肌萎缩侧索硬化症（ALS）。关键专利到期时间：2024年5月5日药物专利数量：4销售额：2021财年1.9亿美元11.Omontys(peginesatide acetate)销售商：Takeda获批时间：2012年3月27日（已退市）适应症和用途：成人透析患者慢性肾病(CKD)所致贫血的治疗。关键专利到期时间：2024年5月12日药物专利数量：612.Ulesfia(benzyl alcohol)销售商：Shionogi获批时间：2009年4月13日适应症和用途：非神经毒性头虱。关键专利到期时间：2024年5月12日药物专利数量：613.Adasuve(loxapine)销售商：Alexza Pharmaceuticals获批时间：2012年12月21日适应症和用途：与精神分裂症或躁郁症相关的躁动。关键专利到期时间：2024年5月20日药物专利数量：514.Children's Advil Allergy Sinus销售商：葛兰素史克获批时间：2004年2月24日适应症和用途：由过敏或普通感冒引起的打喷嚏、瘙痒、流泪、流鼻涕、鼻塞、鼻窦充血、头痛、疼痛或发烧。关键专利到期时间：2024年5月25日药物专利数量：115.Gleolan(aminolevulinic acid hydrochloride)销售商：NX Development Corp.获批时间：2017年6月6日适应症和用途：神经胶质瘤手术期间的光学成像。关键专利到期时间：2024年6月6日16.Ilevro(nepafenac)销售商：Harrow Eye获批时间：2012年10月16日适应症和用途：缓解白内障眼部手术后的眼睛疼痛、刺激和发红。关键专利到期时间：2024年6月8日药物专利数量：317.Vyleesi(Autoinjector)(bremelanotide acetate)销售商：Palatin Technologies获批时间：2019年7月8日适应症和用途：性欲减退症。关键专利到期时间：2024年6月21日药物专利数量：518.Triptodur kit(triptorelin pamoate)销售商：Azurity获批时间：2017年6月30日适应症和用途：性早熟。关键专利到期时间：2024年7月29日药物专利数量：119.Endari(L-glutamine)销售商：Emmaus Medical获批时间：2017年7月7日适应症和用途：镰状细胞性贫血症。关键专利到期时间：2024年7月7日药物专利数量：1销售额：2023年前三季度2250万美元20.Dalvance(dalbavancin hydrochloride)销售商：艾伯维获批时间：2014年5月23日适应症和用途：由敏感革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））引起的急性细菌性皮肤和皮肤结构感染（ABSSSI）的成人患者。关键专利到期时间：2024年7月22日药物专利数量：421.Kimyrsa(oritavancin diphosphate)销售商：艾伯维获批时间：2021年3月15日适应症和用途：成人急性细菌性皮肤和皮肤结构感染（ABSSSI）。关键专利到期时间：2024年8月6日药物专利数量：322.Orbactiv(oritavancin diphosphate)销售商：Melinta Therapeutics获批时间：2014年8月6日适应症和用途：急性细菌性皮肤和皮肤结构感染（ABSSSI）。关键专利到期时间：2024年8月6日药物专利数量：323.Oriahnn(Copackaged)销售商：艾伯维获批时间：2020年5月29日适应症和用途：绝经前妇女与子宫肌瘤（纤维瘤）相关的大量月经出血。关键专利到期时间：2024年9月10日药物专利数量：724.Orilissa(elagolix sodium)销售商：艾伯维获批时间：2018年7月24日适应症和用途：与子宫内膜异位症相关的中度至重度疼痛。关键专利到期时间：2024年9月10日药物专利数量：1025.Somatuline Depot(lanreotide acetate)销售商：Ipsen获批时间：2014年12月16日适应症和用途：胃肠胰神经内分泌肿瘤。关键专利到期时间：2024年9月15日26.Sustol(granisetron)销售商：Heron Therapeutics获批时间：2016年8月9日适应症和用途：化疗引起的恶心/呕吐。关键专利到期时间：2024年9月28日药物专利数量：5销售额：2023年前三季度净产品销售额930万美元27.Prialt(ziconotide acetate)销售商：TerSera获批时间：2004年12月28日适应症和用途：治疗需要鞘内治疗以及对其他治疗（例如全身镇痛药、辅助治疗或IT吗啡）不耐受或无效的患者的严重慢性疼痛。关键专利到期时间：2024年10月1日药物专利数量：328.Ascor(ascorbic acid)销售商：Mcguff获批时间：2017年13月3日适应症和用途：坏血病。关键专利到期时间：2024年10月2日29.Fluorodopa F18(fluorodopa f-18)销售商：Feinstein获批时间：2019年10月10日适应症和用途：对疑似帕金森综合症的成年患者的某些神经细胞进行视觉检测。关键专利到期时间：2024年10月10日30.Byetta(exenatide synthetic)销售商：Amylin Pharmaceuticals/Eli Lilly&Co.获批时间：2005年4月28日适应症和用途：2型糖尿病。关键专利到期时间：2024年11月4日销售额：2019年1.8亿美元31.Exem Foam Kit(air polymer-type a)销售商：ExEm Foam Inc.获批时间：2019年11月7日适应症和用途：检测已知或疑似不孕女性的输卵管通畅性。关键专利到期时间：2024年11月7日32.Nourianz(istradefylline)销售商：Kyowa Hakko Kirin Inc.获批时间：2019年8月27日适应症和用途：帕金森病。关键专利到期时间：2024年11月13日药物专利数量：4销售额：2021年1亿美元33.Macrilen(macimorelin acetate)销售商：诺和诺德获批时间：2017年12月20日适应症和用途：成人生长激素缺乏症的诊断。关键专利到期时间：2024年12月20日药物专利数量：134.Xarelto(rivaroxaban)销售商：Janssen获批时间：2011年7月1日适应症和用途：抗血栓。关键专利到期时间：2024年12月20日药物专利数量：5销售额：2022年24.7亿美元Ref.1.Constantino,A.K.Big pharma is at a crossroads,as J&J,Merck and others prepare to lose heaps of revenue from blockbuster drugs.CNBC.28.01.2024.2.Friedman,Y.United States:These 47 Drugs Face Patent Expirations and Generic Entry From 2024–2025.DrugPatentWatch.com.Retrieved on 31.01.2024.END医药代表交流群扫描下方二维码加入医药代理商转型交流群扫描下方二维码加入

专利到期

100 项与 Emmaus Medical, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Emmaus Medical, Inc. 相关的转化医学

登录后查看更多信息